product name Cidofovir
Description: Cidofovir (also known as HPMPC) is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis with IC50 of 0.94 μM. Cidofovir inhibits human cytomegalovirus (HCMV) infection in cultured cells. Cidofovir is inhibitory to CMV plaque formation even when added to the cells at 48 hr post infection with IC50 of 0.9 μg/mL for Davis and 1.6 μg/mL for AD-169 strains,respectively.
References: Antimicrob Agents Chemother. 1988 Dec;32(12):1839-44; Antiviral Res. 1990 May;13(5):237-52.
279.19
Formula
C8H14N3O6P
CAS No.
113852-37-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
HPMPC
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1941217
| In Vitro |
In vitro activity: Cidofovir inhibits human cytomegalovirus (HCMV) infection in cultured cells. Cidofovir is inhibitory to CMV plaque formation even when added to the cells at 48 hr post infection with IC50 of 0.9 μg/mL for Davis and 1.6 μg/mL for AD-169 strains,respectively. Cidofovir also inhibits herpes simplex virus infection. In addition, Cidofovir blocks cell fusion induced by HSV-1 in monkey kidney cells and blocks the expression of HSV-l-specific proteins and the synthesis of viral DNA. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Cidofovir (5 mg/kg/day) subcutaneously for 5 days significantly reduces average virus infectivity titer in blood, spleen, lung and salivary gland in infected guinea pigs. Cidofovir significantly reduces lymphocytosis and average tissue indexe of spleen in infected animals. Cidofovir suppresses all manifestations (skin lesions, paralysis of the hind legs, and mortality) of hairless mice infected intracutaneously with HSV-1 or HSV-2. The most remarkable feature of Cidofovir is that a single administration of the compound, even as late as 4 days after infection, conferees significant protection against HSV-1 or HSV-2 infection. Cidofovir inhibits growth of the highly aggressive melanoma tumor arising from mouse melanoma B16 cells grafted subcutaneously in C57B16/J mice. |
| Animal model | |
| Formulation & Dosage | |
| References | Antimicrob Agents Chemother. 1988 Dec;32(12):1839-44; Antiviral Res. 1990 May;13(5):237-52. |
